CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 706 enrolled
Drug / intervention
AXS-07drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04068051
NCT04068051Phase 3Completed
CompareCT.gov

An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEIC™ Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults

Axsome Therapeutics, Inc.·interventional·Posted Aug 28, 2019·Updated Oct 10, 2023

In Brief

A Phase 3 clinical trial evaluating AXS-07 for Migraine. Completed, enrolled 706 participants across 51 sites.

Detailed Summary

MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 28, 2019
Enrollment StartJul 6, 2019
Primary CompletionSep 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.8 years ago

Interventions

AXS-07drug

AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.